AUCTORES
Globalize your Research
Mini Reivew | DOI: https://doi.org/10.31579/2640-1053/056
*Corresponding Author: Bakulesh Khamar, R&D department, Cadila Pharmaceuticals Limited, Ahmedabad, India.
Citation: Bakulesh Khamar. Response Predictors for Pembrolizumab in Advanced NSCLC beyond PD-L1 Expression, J. Cancer Research and Celllular Therapeutics, 3(2). Doi: 10.31579/2640-1053/056
Copyright: © 2019 Bakulesh Khamar, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,provided the original author and source are credited.
Received: 08 August 2019 | Accepted: 22 October 2019 | Published: 30 October 2019
Keywords: pembrolizumab; NSCLC; tumor mutation burden; PD-L1 expression; hyper progression; response predictors; tumor immune infiltrate; CD8+ T cells; CD4+ T cells; macrophages
Pembrolizumab has significantly improved outcome of advanced NSCLC. PD-L1 expression has limited utility as a prognostic and predictive biomarker. To improve this several other biomarkers have been evaluated. Useful amongst them are 1. Tumor specific biomarkers include tumor mutation burden, immune cell infiltration (phenotype, genotype, site, type), 2. Changes in cellular, cytokine in peripheral blood. The article provides review of the current status.
Majority of patients diagnosed to have Non-small cell lung cancer (NSCLC) have advanced disease at diagnosis. This makes it difficult to provide curative treatment options. Prior to introduction of pembrolizumab five year survival rate used to be around 5%. This has improved to more than 25% following introduction of pembrolizumab in treatment of NSCLC. This dramatic improvement is seen in patients treated with pembrolizumab having programmed-death ligand 1 (PD-L1) expression of ≥ 50% [1]. Currently pembrolizumab is approved in combination with chemotherapy as a first line treatment of squamous (paclitaxel or nab-paclitaxel and platinum) and non-squamous (pemetrexed and platinum; with no EGFR or ALK genomic tumor aberrations) metastatic NSCLC [2, 3, 4]. It is also approved as a monotherapy in first-line management of patients with PD-L1 expression ≥ 50% having metastatic NSCLC with no Epidermal growth factor receptor (EGFR) or Anaplastic lymphoma kinase (ALK) genomic tumor aberrations [3, 5] and as a second line for the patients whose tumors express PD-L1 (TPS ≥1%) [6]. Currently, PD-L1 expression level measurement by immunohistochemistry is approved as a companion diagnostic for use with pembrolizumab. PD-L1 expression more than 1% [7, 8, 9, 10, 11, 12] in advanced NSCLC is seen approximately 50% [7, 8] with around 30% have it more than 50% [8, 9]. In spite of approval by FDA, it does not have a very high specificity and sensitivity as predictive biomarker. Response to therapy is also seen in absence of PD-L1 expression and failure to respond is also known in those having >50% PD-L1 expression. The response to pembrolizumab is proportional to the amount of PD-L1 expression in non-squamous NSCLC (61.4% vs 47.6% for > 50% and 1-49% respectively) as well as non-selected NSCLC but no significant difference is seen in Squamous NSCLC (60.3% vs 57.9% for > 50% and 1-49% respectively). The survival benefit is also not uniform in spite of use of PD-L1 as a biomarker (Table-1). In spite of all this, more than 10% of patients progress rapidly on therapy. This is not seen with other therapy including chemotherapy [13, 14, 15, 16].
To further improve outcome, efforts are being made to understand parameters contributing to response/no response to therapy with a purpose of better selection of patients as well as identifying novel co-therapies. Most of the information generated so far are based on small studies, and or retrospective analysis of clinical trial samples and so needs to be confirmed in a well-designed study. In this article, current information about various parameters affecting the outcome of pembrolizumab in advanced NSCLC are reviewed.
1. Tumor characteristics:
Pembrolizumab decreases tumor associated immunosuppression by its action on intratumoral PD-1/PD-L1 interaction and proliferation of intratumoral immune cells. This has led to evaluation of tumor characteristics like Tumor mutation burden (TMB), immune infiltrates, expression of other inhibitory molecules etc. for their role in response to therapy.
Tumor mutation burden (TMB) /neoantigen [7, 13, 18, 19, 20, 21, 22]: Nonsynonymous mutations seen in NSCLC appears to be an independent marker of response to anti PD-1 therapy [19]. Hyper mutated tumours are known to be amenable to therapy in absence of PD-L1 expression [19, 22] and higher TMB is considered as an independent marker of response to therapy as well as control of disease [18, 23, 24]. Higher TMB in squamous NSCLC may be responsible for discrepancy in relationship between PD-L1 expression level and outcome. Tumor burden more than 10 is seen in 37% in non-squamous NSCLC and 42% in squamous NSCLC [19]. TMB more than 20 is found to be associated with better outcome (OS 16.8 months vs 8.5 months) compared to TMB<20>
TMB can also be measured in circulating tumor cells and is found to correlate with TMB [26].
Number of Metastatic lesions: Hyper progression is more frequent in patients with more than 2 metastatic lesions [14].
Pre-treatment tumor growth rate: Response to treatment is more frequent in patients with higher pre-treatment growth rate [16].
Immune cell infiltration [13, 20, 27]: Expansion of infiltrating immune cells are known to contribute to response to therapy. Response to anti PD-1 therapy depends on amount, type and site of immune cell infiltration. Based on the site of immune cell infiltrate tumor is designated to one of three immune phenotypes. Inflamed phenotype has abundance of infiltrating immune cells within and surrounding the tumor. This phenotype is associated with response to the therapy. Excluded phenotype has immune cells restricted to margin of the tumor. Desert phenotype has absence of immune cells within tumor (stroma as well as surrounding). Absence of immune cells is associated with lack of the response. However, this is too simplistic as response is dependent on amount and type (phenotype and functional characteristic) of immune infiltrate.
Phenotype of immune cells: Tumor regression following therapy is dependent on decreased immune suppression and increased immunostimulation. Higher CD3 and/or CD8 cells (considered immunostimulant type) are associated with better prognosis and higher amount of FOXP3 and PD-1 represent immunosuppressive microenvironment and is associated with poor outcome.
Both of above (immunostimulant and immunosuppressive) when used as a ratio rather than in isolation e.g. FOXP3/CD8 and PD-1/CD8 ratio provide better prognostication [28]. Lower ratio is associated with increased response rate. Based on above, it is suggested that on immunohistochemistry CD3 T cells ≥ 120 per HPF with n CD8+ T cells and FOXP3+ T cells in a ratio of ≥ 4:1 can be used to prognosticate better outcome [27].
Intratumoral M2-like CD163+ CD33+ PD-L1+ clustered epithelioid macrophages are associated with hyper progression [15].
Genotype (gene expression profile) :
Gene profiling: It is possible to identify desired genes in a pretreatment samples and gene profiling is used to identify a biomarker for response to therapy. Interferon gamma is essential for immune response. Cytolytic activity of immune cells is dependent on secretion of cytolytic enzymes like granzymes and perforins. Based on this Interferon gene expression signature profiles are identified to predict response to therapy [29].
Epigenetic profiling [30]: Epigenetics plays a role in manifestation of gene function. Based on demethylation status of selected CPG loci, epigenetic signature was identified. Positive signature was associated with improved progression free survival (PFS) and OS but not with PD-L1 expression, TMB or CD8+ cells. Negative signature was associated with increased tumor associated macrophages, neutrophils and fibroblasts. Unmethylated T-cell differentiation factor FOXP1 was associated with improved survival. These findings are specific to immunotherapy only.
Proliferative potential: Based on expression of BUB1, CCNB2, CDK1, CDKN3, FOXM1, KIAA0101, MAD2L1, MELK, MKI67 (better known as Ki-67), and TOP2A tumors can be divided into tumors with high proliferative potential, moderate proliferative potential and low proliferative potential. Tumors with a low or high proliferative potential fail to respond (primary resistance). Amongst patients with moderately proliferation potential, PD-L1 expression predicts survival. Higher expression > 50% is associated with better survival compared to PD-L1 expression <50>
Co-expression of inhibitory molecules: Pembrolizumab inhibits action of PD-1 expressing immune cells. PD-1 is one of the inhibitory molecules expressed by T cells. There are other inhibitory molecules like LAG-3 and TIM3, which are also expressed by them. Co-expression of inhibitory molecules like LAG3 with PD-1 is indicative of primary resistance (no response) to therapy. [32, 33]
Classification based on tumor immune microenvironment (TIMIT): Pembrolizumab induces changes in PD-1/PD-L1 axis and infiltrating immune cells. PD-1 is expressed by immune cells and PD-L1 is expressed by tumor cells. Combining the two (PD-1/PD-L1 and CD8+ TIL) and grading their expression as high or low provides a novel way of classifying TIMIT. High CD8+ and low PD-1/PD-L1 predicts better outcome whereas low CD8+ and high PD-1/PD-L1 predicts the worst outcome. TMB is not found to differ in these subtypes [34].
2. Gut microbiome:
Gut microbiome is found to play important role in response to anti PD-1 therapy. In animal studies, they are known to alter T cell and dendritic cell repertoire.
Amount: Patients having higher amount of gut microbiome as revealed by higher bene count respond favourably to treatment. Those who receive antibiotic prior to or during treatment do not respond to anti-PD1 therapy. [13]
Type: Patients having dysbiosis (can be antibiotic induced) fail to respond to therapy [13]. Decreased level of specific microbiome (Ruminococcus bromii, Dialister and Sutterella) and increased level of specific microbiome (Akkermansia muciniphila, Bifidobacterium longum, Faecalibacterium prausnitzi, Propionibacterium acnes, Veillonella parvula,) are seen in patients responding to anti-PD-1 therapy.
3. Changes in Peripheral blood:
There is a constant exchange between tumors and peripheral blood and some of the changes taking place within tumor gets reflected in the peripheral blood. Peripheral blood evaluation offers advantage of having sample at multiple time points before and after therapy. This is not practical for biopsy of tumor tissues and thus provides very useful information. The changes in pre-treatment samples and during treatment are found to be associated with outcome.
Pre-treatment biomarkers: Lymphocytes are key immune cells for response to therapy. Based on markers expressed by them they can be divided into various subtypes with specific function assigned to them. Their relative frequency is also indicative of magnitude of response.
Pre-treatment lymphocyte subtype: Circulating lymphocytes are responsible for immune surveillance and they reflect intratumoral immune surveillance.
Expression of PD1 and FOXP3 are indicative of immunosuppressive phenotype. Their preponderance is associated with poor outcome [35, 36, 37].
Highly differentiated (CD27 negative CD28 low / negative) CD4 cells are indicative of better immunosurveillance and higher count is associated with objective response and better PFS [32]. Base line low percentages of highly differentiated memory CD4 T cells is associated with primary resistance (Lack of response to therapy) [38]. The response rate was 50% in a group with high percentage of highly differentiated memory CD4 cells and improves to > 70% on combining with PD-L1 positivity.
Ratio of peripheral blood cells.
Neutrophil-to-lymphocyte ratio [39, 40, 41]: Lymphocytes play a key role in immune response while neutrophils do not play a significant role. Decrease in lymphocyte as determined by higher neutrophil to lymphocyte ratio is associated with shorter OS and PFS. Ratio of 5.9 or higher prognosticates progression of disease [40].
Monocyte-to-lymphocyte ratio: Similar to neutrophil to monocyte ratio, monocyte to lymphocyte ratio of 11.3 or higher is associated with disease progression [40].
Proliferative response of pretreatment CD4 cells on exposure to anti-PD1 antibody: Response to pembrolizumab is dependent on proliferation of lymphocyte. Attempts has been made to use this phenomenon as a marker for response to therapy. CD4 cell proliferation on exposure to anti-PD1 antibody ex vivo is seen in responders. It is absent in nonresponders. This absence of proliferation is a unique feature and found to persist even after three cycles of pembrolizumab [32].
Red blood cell distribution width (RDW) [42]: Red blood cell distribution width while indicating erythropoiesis is also useful as inflammatory parameters. Increased RDW is found to be associated with poor prognosis. This seems to be an independent marker.
Lung Immune Prognostic Index (LIPI) [13]: LIPI is a combination of two parameters; Neutrophil to lymphocyte ratio (NLR) and lactic dehydrogenase (LDH) level. Based on these two parameters a patient can be assigned to one of the three groups 1. Low NLR and normal LDH 2. High NLR and normal LDH and 3. High NLR and high LDH. Patients with high NLR and LDH (group 3) has the worst prognosis and patients with low NLR (group 1) carry the best prognosis.
Post treatment changes as a prognostic parameters: It is easy to have blood withdrawn at multiple time points during therapy. The attempts are made to analyse various parameters to identify changes in peripheral blood associated with response or its absence. Some of the changes can be detected as early as two-three weeks of initiation of therapy.
Changes in subtypes of immune cells:
Increase in CD8+ve cell in responders.
CD8+ve CD4-ve CD45RO+ve phenotype representing effector memory cells is seen in responders (p=0.002)[43].
CD8+ve cells is seen in responders, particularly expressing CD28 [32].
Increase PD-1 expressing CD4 cells: PD-1 expression on CD4 cells is indicative of immune suppression. Increased expression during therapy is indicative of increased immunosuppression and is associated with progression [35].
Change in Ki67 expressing cells at 3 weeks: Ki67 is a marker of proliferation.
Four fold increase in Ki67 expressing immune cells predict response while no change is seen in non-responders [33]
This increase in Ki67 PD1+ CD8+ T cell subset is twofold in responders[44]
Change in Granzyme-B expressing immune cells: Granzyme- B expression is associated with killing of cancer cells. Responders also have increased Granzyme -B in Ki67 CD8 cells at 3 weeks [33].
Speed of immune response / PD1+ CD8+ T cell response: Early proliferation (4 week) of PD1+CD8+ T cells predicts response to therapy (seen in 57% with ORR) while late or absence of proliferation is associated with absence of response. (84.6% of non-responders) [33].
Cytokine levels:
Decrease in CXCL2 and increase in MMP2 at six weeks there is associated with improved survival [45].
Increase in Serum IL-8 levels suggests increase in immunosuppression and is associated with progression while decrease is associated with response to therapy [46].
Change in serum tumor markers :
Carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), cytokeratin-19 fragments (CYFRA 21-1) and neuron specific enolase (NSE) are serum tumor markers (STM). Decrease in STM is associated with better outcome while increase in STM is associated with poor outcome. (Median PFS 11M vs 6 months with increase < 2 p=0.001).>20 [47].
Change in circulating tumor cells :
Change in PD-L1 expression in circulating tumor cells [48]: PD-L1 expression in circulating cells do not correlate with PD-L1 expression on tumors. However, decrease in PD-L1 expression in circulating tumor cells is associated with response to therapy and increase expression is seen in non responders.
Change in ctDNA: Response to therapy is associated with decrease/non detectable ctDNA at eight weeks in responders. Increase in ctDNA is seen in nonresponders [49].
Circulating tumor cells are also found to provide information about TMB [26].
4. Others
Treatment related adverse events [50]: Generally adverse events seen with pembrolizumab are due to hyper activation of immune system. Their manifestation is associated with response to therapy. Responses seen are durable and persists even when therapy is discontinued for managing adverse events.
Sex [51]: Better efficacy is seen in males compared to females.
Age [52]: Use of pembrolizumab in advanced NSCLC is associated with better outcome in younger than 65 years of age compared to those more than 65 years of age. The difference in HR is > 0.2 for first line therapy. It reduces to 0.13 when used as a subsequent therapy. Age more than 65 years is also associated with hyperprogression of disease [14, 16].
Ongoing research has identified various tumor characteristics, gut microbiome profile, changes reflected in peripheral blood associated with outcome. Changes in peripheral blood can be monitored during therapy also. Currently they are outcome of small studies and/ or retrospective analysis of clinical trials. Their validation will pave way for better selection of patients for monotherapy as well as combination therapy. This will also help in identifying novel co-therapies.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
